Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) FCF Margin: 2010-2025

Historic FCF Margin for Sunshine Biopharma (SBFM) over the last 12 years, with Sep 2025 value amounting to -7.81%.

  • Sunshine Biopharma's FCF Margin rose 1440.00% to -7.81% in Q3 2025 from the same period last year, while for Sep 2025 it was -19.84%, marking a year-over-year increase of 1955.00%. This contributed to the annual value of -40.68% for FY2024, which is 392.00% down from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's FCF Margin is -7.81%, which was up 48.70% from -15.23% recorded in Q2 2025.
  • Sunshine Biopharma's FCF Margin's 5-year high stood at -7.81% during Q3 2025, with a 5-year trough of -1,192.65% in Q3 2021.
  • For the 3-year period, Sunshine Biopharma's FCF Margin averaged around -31.60%, with its median value being -30.04% (2023).
  • The largest annual percentage gain for Sunshine Biopharma's FCF Margin in the last 5 years was 114,713bps (2021), contrasted with its biggest fall of 62,889bps (2021).
  • Quarterly analysis of 5 years shows Sunshine Biopharma's FCF Margin stood at -366.68% in 2021, then soared by 30,474bps to -61.95% in 2022, then surged by 3,190bps to -30.04% in 2023, then slumped by 658bps to -36.63% in 2024, then soared by 1,440bps to -7.81% in 2025.
  • Its FCF Margin stands at -7.81% for Q3 2025, versus -15.23% for Q2 2025 and -19.34% for Q1 2025.